Evidence map›Paper›PMID 30834963›Full record

ArticleEuropean journal of clinical pharmacology2019

Prevalence of medication and off-label medication use in acquired brain injury at a neurorehabilitation hospital.

Raquel Merino, Ana Pérez, Josana Fierro, Rosa Terré

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Treatment Patterns of Anxiety and Posttraumatic Stress Disorder Following Traumatic Brain Injury.The Journal of neuropsychiatry and clinical neurosciences · 2022
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Raquel MerinoPharmacy Service, Institut Guttmann, Neurorehabilitation Hospital, Camí de Can Ruti s/n, 08916, Badalona, Barcelona, Spain. rmerino@guttmann.com.ORCID http://orcid.org/0000-0002-6645-9098
Ana PérezPharmacy Service, Institut Guttmann, Neurorehabilitation Hospital, Camí de Can Ruti s/n, 08916, Badalona, Barcelona, Spain.
Josana FierroPharmacy Service, Institut Guttmann, Neurorehabilitation Hospital, Camí de Can Ruti s/n, 08916, Badalona, Barcelona, Spain.
Rosa TerréNeurorehabilitation Unit, Institut Guttmann, Neurorehabilitation Hospital, Camí de Can Ruti s/n, 08916, Badalona, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePatients who suffer acquired brain injury (ABI) require a great variety of drugs. Furthermore, the lack of evidence on the medication effects in this type of patient increases off-label prescription. The aim of this study was to describe the pattern of medication use and the practice of prescribing off-label drugs in these patients.

methodsA cross-sectional study was conducted in patients with ABI, of either traumatic or non-traumatic cause, admitted to a neurorehabilitation hospital for rehabilitation. Demographic and clinical data and prevalence of medication use and off-label prescription were collected.

resultsThe majority of the studied patients (85.2%) were considered polymedicated since they were prescribed ≥ 6 drugs concomitantly. In traumatic brain injury (TBI) patients, antidepressants (81.5%) were the Anatomical Therapeutic Chemical (ATC) group's most prescribed versus antithrombotic agents (80.5%) in non-traumatic brain injury (N-TBI) patients. Up to 37.3% of all active substances prescribed in TBI patients were off-label compared with 24.9% in N-TBI patients. The most prescribed off-label active substances in both groups were those related to the Nervous System (N) ATC group to treat neurobehavioural problems.

conclusionA multidisciplinary pharmacotherapeutic follow-up of these patients would be essential to address the high prescription rate of medications and the off-label prescription practice. In this way, medication problems related to polypharmacy could be minimised and the benefit-risk ratio of prescribed off-label drugs could be ensured according to the available medical evidence.

Indexed as

PolypharmacyAdolescentAdultAgedBrain InjuriesChildDrug UtilizationFemaleHospitalizationHospitals, RehabilitationHumansMaleMiddle AgedNeurological RehabilitationOff-Label UseYoung AdultAcquired brain injuryNeurobehaviouralNeurorehabilitationOff-label prescriptionPolypharmacy

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.